Sumitomo Pharma Oncology’s DSP-5336 Receives the US FDA’s Orphan Drug Designation for the Treatment of Acute Myeloid Leukemia
- The US FDA has granted ODD to DSP-5336 which is currently being studied in a P-I/II dose escalation & dose expansion study for patients with r/r AML with/out MLL rearrangement or NPM1 mutation across the US & Japan
- In preclinical studies, patients treated with DSP-5336 showed selective growth inhibition in human acute leukemia cell lines with MLL rearrangements or NPM1 mutations
- DSP-5336 is a small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein. The therapy is designed to identify novel therapeutic options to improve patients outcomes for the treatment of AML
Ref: PR Newswire | Image: Sumitomo Pharma
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at email@example.com.